DMT-310 is under clinical development by Dermata Therapeutics and currently in Phase III for Acne Vulgaris. According to GlobalData, Phase III drugs for Acne Vulgaris have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how DMT-310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DMT-310 overview
DMT-310 is under development for the treatment of acne vulgaris, psoriasis and it was under development for the treatment of papulopustular rosacea. The drug candidate is a variant of sponge administered topically. It acts by targeting interleukin 17A and 17F and is being developed based on the Spongilla platform technology.
See Also:
Dermata Therapeutics overview
Dermata Therapeutics is a biotechnology company. It develops and commercializes treatments for medical and aesthetic skin conditions. The company investigates its lead product candidate DMT310, a natural source of spongilla lacustris with multiple active components to treat inflammatory skin diseases including acne, psoriasis and rosacea. Dermata Therapeutics evaluates DMT400, a combination regimen of biologic molecules against various skin diseases and cosmetic applications; and DMT410 drug developed in combination with botulinum toxin for the treatment of hyperhidrosis and aesthetics. The company utilizes its proprietary Spongilla platform technology to develop its products. Dermata Therapeutics is headquartered in San Diego, California, the US.
For a complete picture of DMT-310’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
